Certolizumab Pegol

Introduction Overview

Generic Name

certolizumab pegol

Brand Name

Cimzia

Dosage Form

injection

Drug Class

TNF alfa inhibitors

Pharmacokinetics

Absorption:
Certolizumab pegol is administered via subcutaneous injection, enabling direct absorption into the systemic circulation via the lymphatic system and capillary uptake. Peak plasma concentrations are generally reached within 54 to 171 hours post-dose depending on dosing regimen and patient factors. Bioavailability following subcutaneous administration is approximately 80%, which is relatively high for a monoclonal antibody, indicating efficient absorption from the injection site. Absorption can be influenced by local blood flow, injection site, and the presence of anti-drug antibodies, which may alter pharmacokinetic profiles over the course of therapy.

Distribution:
Following absorption, certolizumab pegol distributes primarily within the vascular and interstitial compartments due to its large molecular size (~91 kDa). Due to PEGylation (attachment of polyethylene glycol), the molecule exhibits an increased hydrodynamic size, resulting in reduced renal clearance and extended systemic circulation. The drug does not significantly cross the blood-brain barrier. Volume of distribution approximates plasma volume, reflecting limited distribution beyond the extracellular space. PEGylation contributes to decreased immunogenicity and extended half-life by shielding the molecule from proteolytic enzymes and decreasing uptake by the reticuloendothelial system.

Metabolism:
As a pegylated Fab' fragment of a humanized monoclonal antibody, certolizumab pegol undergoes proteolytic degradation by widespread catabolic pathways, including lysosomal processing within endothelial and phagocytic cells. The protein backbone is broken down into small peptides and amino acids, which are recycled or eliminated. The PEG component is excreted unchanged primarily via the kidneys. There is no involvement of cytochrome P450 enzymatic pathways, reducing potential for metabolic drug interactions.

Elimination:
Certolizumab pegol has a terminal half-life of approximately 14 days, consistent with other TNF inhibitors but slightly prolonged due to PEGylation. Elimination occurs predominantly through catabolism to small peptides and amino acids, rather than renal excretion of the intact molecule. PEG moiety is renally cleared. Steady state concentrations are achieved after approximately 8 weeks of consistent dosing. Factors such as anti-drug antibody development can increase clearance, necessitating monitoring for possible loss of efficacy. The drug may be detected in plasma up to 56-70 days post last dose. There is no significant elimination through bile or feces.

Dosage Forms

Available Dosage Forms:
- 200 mg/mL solution in a single-dose prefilled syringe.
- 200 mg lyophilized powder in a single-dose vial that requires reconstitution with sterile water for injection.

Dosages for Adults and Adolescents:
- Rheumatoid Arthritis (Adults): Initial dose of 400 mg subcutaneously as two injections of 200 mg each at weeks 0, 2, and 4; maintenance dose of 200 mg every other week; or 400 mg every 4 weeks as alternative maintenance.
- Psoriatic Arthritis (Adults): Same regimen as rheumatoid arthritis.
- Ankylosing Spondylitis (Adults): Initial dosing identical to above, maintenance dosing either 200 mg every 2 weeks or 400 mg every 4 weeks.
- Crohn's Disease (Adults): Initial 400 mg subcutaneously (two injections of 200 mg) at weeks 0, 2, and 4; maintenance 400 mg every 4 weeks.
- Plaque Psoriasis (Adults): For patients ≤90 kg, 400 mg (two injections of 200 mg) at weeks 0, 2, and 4 followed by 200 mg every other week; for others, 400 mg every other week.
- Non-Radiographic Axial Spondyloarthritis (Adults): Initial dosing similar to ankylosing spondylitis; maintenance dosing 200 mg every 2 weeks or 400 mg every 4 weeks.

Specific Patient Populations:
- Polyarticular Juvenile Idiopathic Arthritis (Patients ≥2 years): Weight-based dosing every other week:
* 10 kg to < 20 kg: 100 mg initially, weeks 2 and 4; maintenance 50 mg every other week.
* 20 kg to < 40 kg: 200 mg initially, weeks 2 and 4; maintenance 100 mg every other week.
* ≥ 40 kg: 400 mg initially, weeks 2 and 4; maintenance 200 mg every other week.

Clinical Guidelines:
- Injection sites should be rotated between the thigh and abdomen avoiding bruised, tender, red, or hard skin.
- For 400 mg doses (two injections), injections must be in separate sites.
- Cimzia can be administered as monotherapy or with non-biologic DMARDs but not recommended concurrently with other biologics or TNF inhibitors.
- Prefilled syringes have a single-use only designation.
- Store unopened syringes and vials refrigerated at 2°C to 8°C (36°F to 46°F), protect from light, do not freeze.
- Syringes can be kept at room temperature (up to 25°C) for a single period of up to 7 days, but must not be refrigerated again.

Mechanism Of Action

Certolizumab pegol (Cimzia) exerts its therapeutic effects through selective binding to tumor necrosis factor alpha (TNFα), a pivotal pro-inflammatory cytokine involved in the immune-mediated pathogenesis of several autoimmune diseases. Unlike full monoclonal antibodies, certolizumab pegol is a PEGylated Fab' fragment devoid of an Fc region, enabling it to neutralize TNFα without eliciting Fc-mediated effector functions such as complement activation or antibody-dependent cellular cytotoxicity, potentially reducing certain adverse immune responses.

At the molecular level, Cimzia binds with high affinity to both soluble and transmembrane forms of TNFα, thereby preventing TNFα interaction with its receptors (TNFR1 and TNFR2) on target cells. This blockade interrupts downstream signaling pathways that lead to the expression of inflammatory mediators, adhesion molecules, and enzymes such as matrix metalloproteinases that contribute to tissue destruction and chronic inflammation.

By inhibiting TNFα, certolizumab pegol diminishes leukocyte infiltration, cytokine release, and systemic inflammatory processes characteristic of conditions like rheumatoid arthritis, Crohn's disease, and psoriasis. The PEGylation component enhances plasma half-life and reduces immunogenicity, allowing sustained TNFα suppression with less frequent dosing compared to unmodified Fab fragments.

Clinically, this inhibition translates into reduced joint inflammation, tissue damage, and symptom amelioration. Comparative studies demonstrate that Cimzia's mechanism overlaps with other TNF inhibitors like adalimumab and infliximab; however, the lack of Fc region potentially decreases placental transfer and reduces fetal exposure, making it uniquely favorable in pregnancy. Ongoing research explores differential immunologic impacts and long-term safety profiles relative to other biologics, highlighting its growing role in targeted immunomodulation.

Pharmacological Actions

Neutralizes tumor necrosis factor alpha (TNFα) by high-affinity binding.
Inhibits TNFα mediated inflammatory signaling pathways.
Reduces leukocyte migration and inflammatory cell infiltration.
Suppresses synthesis of pro-inflammatory cytokines, chemokines, and adhesion molecules.
Prevents tissue destruction associated with autoimmune inflammatory processes.
PEGylation prolongs plasma half-life by reducing renal clearance and proteolytic degradation.
Lacks Fc region, minimizing complement activation and antibody-dependent cytotoxicity.
Modulates immune response leading to decreased disease activity in autoimmune conditions.
Reduces systemic markers of inflammation such as C-reactive protein (CRP).
Improves clinical symptoms and physical function in inflammatory diseases.
Decreases radiographic progression of joint damage in rheumatoid arthritis.
Has potential to disrupt granuloma maintenance, necessitating tuberculosis screening.
Does not undergo cytochrome P450 metabolism, limiting pharmacokinetic drug interactions.
Immunosuppressive activity may increase susceptibility to infections.
Limited placental transfer compared to full antibody TNF inhibitors.

Therapeutic Or Clinical Uses

Treatment of moderate to severe active Crohn's disease in adults with inadequate response to conventional therapies.
Management of moderate to severe active rheumatoid arthritis in adult patients.
Treatment of active psoriatic arthritis in adult patients.
Therapy for active ankylosing spondylitis in adult patients.
Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Management of active non-radiographic axial spondyloarthritis with objective signs of inflammation in adults.
Treatment of active polyarticular juvenile idiopathic arthritis in patients aged 2 years and older with weight-adjusted dosing.
Used to reduce signs and symptoms of inflammation and improve physical function in autoimmune diseases.
Employed as monotherapy or in combination with non-biologic disease-modifying antirheumatic drugs (DMARDs).
Utilized to maintain clinical response and remission in chronic inflammatory conditions.
Off-label use may include other TNFα-mediated inflammatory diseases, subject to clinical discretion.
Alternative for patients intolerant or refractory to other TNF inhibitors or biologics.
Part of induction and maintenance therapy regimens tailored to specific autoimmune disorders.
May be preferred in pregnancy due to low placental transfer compared to other TNF inhibitors.
Provides symptom relief and disease activity reduction in systemic inflammatory conditions.

Side Or Adverse Effects

Injection site reactions including pain, redness, swelling, and bruising.
Common adverse effects such as rash, upper respiratory tract infections, nasal congestion, sneezing, and sore throat.
Serious infections including bacterial, viral, fungal, and opportunistic infections; symptoms include fever, chills, cough, and fatigue.
Risk of reactivation of latent tuberculosis; necessitates pre-treatment screening.
Rare occurrences of lymphoma and other malignancies, including hepatosplenic T-cell lymphoma.
Allergic reactions including urticaria, anaphylaxis, facial swelling, and respiratory difficulty.
Potential development of lupus-like syndrome marked by rash and joint pain.
Neurological adverse effects like new or worsening demyelinating disorders (e.g., multiple sclerosis).
Hematologic abnormalities such as anemia, leukopenia, and thrombocytopenia leading to bruising or bleeding.
Hepatotoxicity manifesting as elevated liver enzymes, jaundice, or abdominal pain.
Gastrointestinal symptoms including diarrhea and abdominal pain.
Potential exacerbation of congestive heart failure in predisposed patients.
Uncommon hair loss (alopecia totalis) reported as an immune-mediated effect.
Injection site pain or burning sensation upon administration.
Possible hypersensitivity to inactive ingredients including latex allergy consideration.

Precautions

Perform tuberculosis screening before initiation and monitor throughout therapy due to risk of reactivation.
Assess for chronic or active infections prior to starting treatment; avoid use in presence of serious infections.
Cautiously use in patients with history of malignancies, giving consideration to lymphoma risk.
Monitor for signs of hypersensitivity reactions and discontinue upon severe allergic manifestations.
Avoid simultaneous administration with other biologic DMARDs or TNF inhibitors to reduce infection risk.
Exercise caution in patients with congestive heart failure; monitor clinical status closely.
Pregnancy use only if potential benefits justify potential risks; register on pregnancy exposure registries if possible.
Not recommended for use in children under 2 years old except for pJIA with weight-based dosing.
Patient counseling on infection risk and importance of promptly reporting symptoms of infection.
Avoid live vaccines during treatment and until sufficient immune recovery after discontinuation.
Monitor liver function periodically due to hepatotoxicity risk.
Rotate injection sites to minimize local site reactions and tissue trauma.
Use caution in patients with nervous system disorders or history of demyelinating diseases.
Inform patients regarding appropriate storage and handling to maintain drug stability and effectiveness.
Ensure patients have proper training on self-injection techniques to reduce administration errors.

Warnings

Increased susceptibility to serious and sometimes fatal infections including sepsis, tuberculosis, and opportunistic infections.
Potential development of lymphoma and other malignancies; risk may be higher in younger patients with inflammatory bowel disease.
Hypersensitivity reactions including anaphylaxis, urticaria, and angioedema have been reported.
Do not use live vaccines concurrently due to compromised immune response.
Discontinue use and seek immediate medical attention for symptoms indicating infection or allergic reaction.
Use with caution in patients with chronic or latent hepatitis B due to risk of viral reactivation.
May cause new or exacerbation of neurological disorders resembling multiple sclerosis.
Potential risk of worsening congestive heart failure; monitor for new or aggravated signs including edema and dyspnea.
Withdrawal of therapy may be necessary in severe adverse immune-mediated reactions or infections.
Increased risk of bleeding; patients should avoid activities increasing risk of injury.
Report any sudden flu-like symptoms, weight loss, or unusual swelling promptly to healthcare provider.
Avoid use if prior serious hypersensitivity to certolizumab or formulation excipients.
Clinical monitoring recommended for hematologic abnormalities such as pancytopenia.
Patients should be informed of the risk of injection site reactions and ways to manage mild symptoms.
Delayed hypersensitivity reactions may occur; patient education regarding symptom recognition is essential.

Contraindication

Known hypersensitivity to certolizumab pegol or any of the excipients in the formulation.
Active severe infections including sepsis, abscesses, or opportunistic infections.
Concurrent administration with other TNF blockers or biologic DMARDs due to increased infection risk.
Patients with active tuberculosis who have not received adequate treatment.
Individuals with demyelinating diseases such as multiple sclerosis may be at increased risk of exacerbation.
Severe congestive heart failure (NYHA class III/IV) as treatment may worsen condition.
Patients with a history of hypersensitivity reactions to other TNF inhibitors may have cross-reactivity.
Use during administration of live vaccines is contraindicated.
Known immunodeficiency disorders not adequately controlled or monitored.
Pregnancy status unknown or not evaluated in certain cases; use cautiously with informed risk/benefit analysis.
Do not use if product is expired, contaminated, or syringe compromised.
Hypersensitivity to latex (some formulations contain latex in syringe needle cover) prohibits use.
Active malignancy or history of malignancy should be evaluated prior to therapy; contraindicated if high risk.
Use is contraindicated if patient exhibits signs or symptoms of systemic infection.
Absolute contraindication in patients with known allergy to polyethylene glycol or polysorbates present.

Drug Interactions

Concurrent use with other TNF inhibitors or biologic DMARDs (e.g., abatacept, adalimumab, etanercept, golimumab, infliximab, natalizumab, rituximab) increases risk of serious infections and immunosuppression.
Potential reduced efficacy of live vaccines when co-administered; live vaccines are contraindicated during treatment.
Immunosuppressive agents may have additive effects increasing infection risk when used concomitantly.
No significant interactions via cytochrome P450 enzymes as certolizumab pegol is degraded proteolytically.
Concomitant use with systemic corticosteroids or methotrexate is common but requires monitoring for increased immunosuppression.
No known direct drug interactions with common over-the-counter medications, vitamins, or herbal supplements, but caution advised.
Potential interaction with anticoagulants or antiplatelet agents may increase bleeding risk; monitor accordingly.
Co-administration with drugs affecting immune system or bone marrow function could exacerbate leukopenia or other hematologic adverse effects.
No documented interaction with CYP450 inducers or inhibitors, reducing concerns for metabolic drug-drug interactions.
Combining with other immunomodulators may require dose adjustment and vigilant infection surveillance.
Live attenuated vaccines should not be given during or for a period after treatment cessation.
Certain herbal products with immunomodulatory properties could have unpredictable effects; consult healthcare provider before combining.
No specific data on interactions with commonly used antibiotics or antifungals, but infection risk necessitates careful monitoring.
Drug interactions with agents causing hepatotoxicity may compound liver-related adverse effects.
Careful monitoring recommended when combining with nephrotoxic drugs due to potential additive renal effects.

Preparations Of The Drug

Cimzia lyophilized powder 200 mg single-dose vial requiring reconstitution with sterile water for injection prior to subcutaneous administration.
Cimzia 200 mg/mL solution in prefilled glass syringe, single-use, ready-to-administer for subcutaneous injection.
Prefilled syringes contain certolizumab pegol along with sodium acetate, sodium chloride, and Water for Injection as inactive ingredients.
Lyophilized powder formulation includes lactic acid, polysorbate, and sucrose as stabilizers and excipients.
Product packaging includes instructions for reconstitution (if powder), handling, storage, and disposal to ensure safety and efficacy.
Syringe needle cover contains latex; caution required in patients with latex allergy.
Prefilled syringes designed for self-administration with proper training; pre-measured dose reduces dosing errors.
Storage requires refrigeration at 2°C to 8°C and protection from light; do not freeze to preserve biologic activity.
Once removed from refrigeration, prefilled syringes may be kept at room temperature (up to 25°C) for no more than 7 days.
Discard any unopened or partially used syringes after this period to prevent degradation and contamination.
Single-dose vial and syringe preparations ensure dosing flexibility for weight-based and adult dosing regimens.
Sterile, pyrogen-free preparations conforming to FDA manufacturing standards to minimize infection risk.
Package labeling provides detailed pharmacological and safety information as per regulatory requirements.
Each preparation includes lot number and expiration date for tracking and quality assurance.
Patient support materials often provided to educate on correct injection technique and proper storage.